Applied Therapeutics, Inc.
APLT
$0.10
-$0.01-7.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 122.00K | 266.00K | 456.00K | -211.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 122.00K | 266.00K | 456.00K | -211.00K |
| Cost of Revenue | 39.06M | 44.28M | 44.36M | 48.74M | 52.35M |
| Gross Profit | -38.06M | -44.16M | -44.10M | -48.29M | -52.56M |
| SG&A Expenses | 61.56M | 67.23M | 64.63M | 56.01M | 39.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.61M | 111.51M | 109.00M | 104.75M | 92.07M |
| Operating Income | -99.61M | -111.39M | -108.73M | -104.30M | -92.28M |
| Income Before Tax | -18.14M | -67.74M | -43.51M | -105.62M | -187.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.14 | -67.74 | -43.51 | -105.62 | -187.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.14M | -67.74M | -43.51M | -105.62M | -187.31M |
| EBIT | -99.61M | -111.39M | -108.73M | -104.30M | -92.28M |
| EBITDA | -99.61M | -111.39M | -108.73M | -104.30M | -92.28M |
| EPS Basic | -0.12 | -0.47 | -0.30 | -0.82 | -1.47 |
| Normalized Basic EPS | -0.08 | -0.29 | -0.19 | -0.51 | -0.92 |
| EPS Diluted | -0.13 | -0.47 | -0.45 | -0.97 | -1.62 |
| Normalized Diluted EPS | -0.08 | -0.29 | -0.19 | -0.51 | -0.92 |
| Average Basic Shares Outstanding | 579.90M | 578.68M | 577.53M | 558.06M | 524.13M |
| Average Diluted Shares Outstanding | 579.90M | 578.68M | 585.99M | 566.52M | 532.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |